Molecular Insight Pharmaceuticals has asked German firm Eckert & Ziegler to develop a new cancer drug using its radiotherapeutic compound, Onalta, which is a product candidate for the treatment of some neuroendocrine tumors. Eckert & Ziegler will combine Onalta with the 90Y edotreotide radioisotope to produce the cancer treatment.

Full Story:

Related Summaries